SynAct Pharma AB (SYNACT) Stock Statistics & Valuation Metrics

SynAct Pharma AB has a market cap or net worth of kr1.09B. The enterprise value is kr1.02B.

SynAct Pharma AB has 49,874,542 shares outstanding. The number of shares has decreased by -2.65% in one year.

SynAct Pharma AB’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -33.64%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, SynAct Pharma AB had revenue of 0.00 and earned -82.40M in profits. Earnings per share was -2.08.

In the last 12 months, operating cash flow was -78.04M and capital expenditures 0.00, giving a free cash flow of -78.04M billion.

SynAct Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

SynAct Pharma AB upcoming earnings date is ―, ―.

SynAct Pharma AB as a current ratio of 3.30, with Debt / Equity ratio of 0.91%

In the past 12 months, SynAct Pharma AB has paid -8.42M in taxes.

SynAct Pharma AB EV to EBITDA ratio is -19.18, with an EV/FCF ratio of -3.31.

SynAct Pharma AB has kr51.16M in cash and marketable securities with kr1.64M in debt, giving a net cash position of -kr49.52M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for SynAct Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―